Durvalumab gets FDA breakthrough status for bladder cancer

17 Feb 2016

The U.S. Food and Drug Administration has granted breakthrough therapy designation to AstraZeneca's biggest new drug hope ‍durvalumab as a treatment in bladder cancer, the drug maker reported.


The experimental medicine is a so-called PD-L1 therapy that fights cancer by boosting the immune system. Breakthrough therapy designation expedites the development and review of medicines intended to treat serious or life-threatening diseases.

Durvalumab is also being developed as a treatment for lung, head and neck, gastric, pancreatic, liver and blood cancers.

Source: Reuters

Login to your account

Did you forget your password?